An affiliate of Irish biopharmaceutical company Horizon Pharma has entered into a definitive agreement with German pharmaceutical company Boehringer Ingelheim International, to take over the rights to interferon gamma-1b.

Boehringer commercialises interferon gamma-1b in almost 30 countries, mainly across Europe and the Middle East under the trade names IMUKIN, IMUKINE, IMMUKIN and IMMUKINE.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Horizon Pharma president and chief executive officer Timothy Walbert said: "Obtaining worldwide rights for interferon gamma-1b solidifies our continued investment in the medicine, and pending the outcome of clinical studies investigating it in Friedreich’s ataxia and advanced solid tumours, such as kidney and bladder cancer, strengthens our ability to expand its potential global use."

Under the deal, Horizon Pharma has already paid €5m to Boehringer Ingelheim on signing the agreement.

"Obtaining worldwide rights for interferon gamma-1b solidifies our continued investment in the medicine, and … strengthens our ability to expand its potential global use."

Upon closing of the transaction, the Irish biopharmaceutical company will also have to pay another €20m to gain the rights for interferon gamma-1b in all territories outside of Canada, the US and Japan.

See Also:

The current deal with Boehringer has enabled Horizon to begin investing in associated manufacturing, regulatory, supply chain, as well as commercial activities for interferon gamma-1b.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As per the terms of another agreement Horizon Pharma entered into with an undisclosed third party, the biopharmaceutical company has licensed the European, the US and Canadian intellectual property rights for interferon gamma-1b for the treatment of Friedreich’s ataxia.

At present, interferon gamma-1b is not indicated or approved to treat Friedreich’s ataxia.